Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
Part of paid clinical trials in Bakersfield, California.
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Study ID
- NCT07214740
- Phase
- PHASE3
- Status
- Completed
Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- APL-2, Pegcetacoplan — DRUGComplement (C3) Inhibitor
Study Details
This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)
Key Dates
- Start date
- Oct 24, 2025
- Status verified
- Dec 2025
- Primary completion
- Dec 12, 2025
- Completion
- Dec 12, 2025
Study Design
- Enrollment
- 44 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Pegcetacoplan, 15 mg/100 μL (single dose), intravitreal injection via prefilled syringeThis is a 30-day, phase 3b, single-arm, open-label, multicenter study to evaluate the safety of IVT pegcetacoplan administered via PFS in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study consists of a screening/baseline visit at day 1, a follow-up call at day 7, and an end of study visit at day 30.
Primary Outcome Measure
To evaluate safety and tolerability of intravitreal (IVT) pegcetacoplan administered via PFS by assessing incidence of ocular treatment-emergent adverse events (TEAEs) in the study eye [ Time Frame: Up to Day 30 ]
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| California Retina Consultants | Bakersfield | California | 93309 | - |
| California Retina Consultants | Oxnard | California | 93036 | - |
| Austin Retina Associates | Austin | Texas | 78705 | - |
| Retina Consultants of Texas | Katy | Texas | 77494 | - |
| Retina Consultants of Texas | Woodland | Texas | 77384 | - |
Related coverage on Hipa.ai
- Syfovre (Pegcetacoplan) Phase 3 Trial for Geographic Atrophy Primary CompletionPegcetacoplan · Dec 12, 2025 · ClinicalTrials.gov
Find similar trials in Bakersfield, CA
Related Studies
- Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular DegenerationRecruiting · i-Lumen Scientific AUS PTY LTD · Manchester, Connecticut
- Phase 2 Study of ADX-038 in Participants With Geographic AtrophyPHASE2 · Recruiting · ADARx Pharmaceuticals, Inc. · Gilbert, Arizona
- A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)Recruiting · Complement Therapeutics · Mountain View, California
- A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioPHASE2 · Recruiting · Apellis Pharmaceuticals, Inc. · Gilbert, Arizona